All
Derms talk about goals for 2008
January 1st 2008The year 2008 is under way. It's a year that promises a lot of discussion of healthcare delivery and costs, and promises of change. On Call wondered what direction dermatologists expect to take in their practices in the coming year. What are their priorities for their practices? What are their New Year's resolutions for their practices? For several of the dermatologists who spoke to On Call, the business end of their practice is slated to get a lot of attention this year as they try to run their offices as efficiently as possible.
Cosmeceutical hype does not benefit our patients
January 1st 2008A recent headline in Dermatology Times read, "Niacin boosts IPL outcome." In small print, the sub-headline read, "Small study sees non-statistical improvement in skin texture." The summary of the article, called "Quick Read," had the following statement: "A niacin-based skincare cosmeceutical regimen combined with intense pulsed light (IPL) treatments offers better skin rejuvenation outcomes than IPL alone, a new study suggests."
Derm concerns prompt FDA to review postmarket data on facial fillers
January 1st 2008National report - Prompted by dermatologists' concern over the safety of a recently approved permanent dermal filler, the FDA has formed a team to study postmarket experience with all newer dermal fillers, focusing mainly on the permanent variety.
Genetic flaw, HPV cause unmanageable tree-like growths
January 1st 2008When Discovery Channel invited Anthony Gaspari, M.D., to diagnose what might be causing tree-like structures to grow on an Indonesia man, the suspicion was an extreme case of epidermodysplasia verruciformis. But Dr. Gaspari, professor and chairman of the department of dermatology, University of Maryland School of Medicine, Baltimore, found the man was disfigured by disseminated HPV-2, infection. A genetic flaw robbed Dede, the Indonesian, of his ability to ward off warts that had spread like wild fire around his body-even to the point of causing tree-limb-like cutaneous horns.
P&G researchers sequence genome of dandruff-causing fungus
December 4th 2007Cincinnati - Reuters reports that researchers at Procter & Gamble say they have sequenced the genome of Malassezia globosa, a fungus that grows on the skin of between 50 percent and 90 percent of the population, causing dandruff and other skin conditions.
Clinical trial to evaluate efficacy of Isolagen Therapy for treating acne scars
December 4th 2007Exton, Pa. - Biotech company Isolagen, based here, has announced the initiation of a phase 3 clinical study to test Isolagen Therapy for the treatment of moderate to severe acne scars, PRNewswire reports.
Study shows effectiveness of golimumab in treating psoriatic arthritis
December 4th 2007Boston - Results of what is reportedly the largest phase 3 study ever conducted with a biologic treatment suggest that patients with active psoriatic arthritis (PsA) achieve significant, sustained improvements in joint and skin manifestations of the disease after monthly subcutaneous injections of investigative golimumab, DocGuide.com reports.
NIH awards grant to Cleveland institutions for psoriasis research
December 4th 2007Cleveland - The Case Western Reserve University medical school and University Hospitals Case Medical Center have received a five-year, $6.37 million grant from the National Institutes of Health to find new treatments for psoriasis, Crain’s Cleveland Business reports.
Doctor objects to AAD logo appearing on sun protection products
December 1st 2007The American Academy of Dermatology announced in May 2007 that it had launched its Seal of Recognition program, in which the Academy charges companies thousands of dollars for the right to display the Academy's logo on sun protection products that meet the Academy's criteria. Academy members who back the program say it is a noble cause that will greatly fuel the organization's skin cancer education efforts.
Can studies funded by manufacturers yield valid, objective results?
December 1st 2007With the decreases in government funding of medical trials, manufacturers of the products being tested finance more and more clinical trials, whether for medication, therapies or equipment. Tests are obviously needed to determine the effectiveness and safety of new products in order to make medical progress. That system, however, can put unpredictable pressure on physicians conducting the trials.
Your Web site: Do you need the bells and whistles?
December 1st 2007Websites range from those structured as online brochures to the more complicated interactive sites. Whether you need the bells and whistles of interaction depends on your goals, how much you want to spend and how much effort you plan to focus on the web.
Senators ponder ethical conflicts of doctor-drug company relationships
December 1st 2007Congress has been warned that many doctors are "on the take" from big pharmaceutical companies, which pay them in one way or another to prescribe their drugs to patients, and are "at risk of corruption" while endangering the lives of patients.
Defining terms: Dysyplastic debate continues
December 1st 2007In the Letters section of the October 2007 issue of Dermatology Times, both Craig G. Burkhart, M.D., and Michael H. Coverman, M.D., do not directly address two important points in the debate regarding "dysplastic" nevi. Clinical utility of a concept derives from its prognostic and therapeutic implications. Specifically, the utility of the concept of dysplastic nevi is that they are a significant risk factor for cutaneous melanoma.[1,2] This concept is analogous to hypercholesterolemia and hypertension being asymptomatic risk factors for cardiovascular disease and not diseases in and of themselves.